Longeveron rises on positive results from Alzheimer's treatment trial
20/12/2023 13:17
** Shares of therapy developer Longeveron LGVN.O rise
~13.8% to $2.20 premarket
** Co says a mid-stage trial evaluating its therapy
Lomecel-B showed improved cognitive function in patients with
Alzheimer's disease
** Says the therapy countered loss of brain volume, reduced
brain neuroinflammation and improved cerebral blood flow
** Up to last close, stock down 39.4% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))